Arrowhead Pharma Stock Price, News & Analysis

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ending June 30, 2021. Investors can access the live audio on the Company's website. A replay will be available shortly after the call concludes. Arrowhead focuses on developing therapies that utilize RNA interference to address intractable diseases by silencing specific genes.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced on July 1, 2021, the approval of "inducement" grants to 42 new employees by its Board of Directors’ Compensation Committee. These grants, totaling up to 157,000 restricted stock units, are outside of the company's stockholder-approved equity incentive plans and vest annually over four years. Arrowhead develops RNAi-based therapeutics targeting intractable diseases by silencing specific genes, aiming for effective gene expression inhibition.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced positive interim results from its Phase 1b AROHIF21001 study, evaluating ARO-HIF2 for treating clear cell renal cell carcinoma (ccRCC). The study has enrolled 17 patients, with 9 having evaluable tumor samples. Results showed that 7 of 9 patients had reductions in HIF2α protein levels, averaging 48%. Notably, one patient experienced a partial response with a 65% tumor shrinkage. Arrowhead is currently enrolling the third cohort and plans to present further data at an upcoming medical congress.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced a voluntary pause of the AROENaC1001 clinical study, a Phase 1/2 trial for its RNA interference therapy targeting cystic fibrosis. This decision follows preliminary findings from chronic toxicology studies indicating unexpected local lung inflammation in rats. The company has halted new patient screenings and further dosing while waiting for comprehensive data from ongoing toxicology studies. Despite this setback, Arrowhead remains focused on advancing its other eight clinical candidates and expanding its preclinical initiatives.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated dosing for the first patient in its Phase 2b clinical trial, AROANG3-2001, aimed at evaluating the safety and efficacy of ARO-ANG3 for treating mixed dyslipidemia. The study will enroll about 180 participants and assess three dose levels (50 mg, 100 mg, and 200 mg) against a placebo. ARO-ANG3 targets the inhibition of ANGPTL3 to reduce triglycerides and LDL cholesterol, potentially addressing cardiovascular risks in patients with mixed dyslipidemia.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced positive interim results from the AROAAT2002 study, showcasing 48-week liver biopsy outcomes for the investigational RNAi therapeutic ARO-AAT, developed in collaboration with Takeda. The study observed significant reductions in mutant AAT protein levels, with a median decrease of 80.1% in total Z-AAT. Patients also showed improvements in liver fibrosis, with 6 out of 9 achieving stage improvements. ARO-AAT was well tolerated, indicating a promising therapeutic option for patients suffering from alpha-1 antitrypsin deficiency.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented promising preclinical data for ARO-DUX4, an RNA interference therapeutic targeting facioscapulohumeral muscular dystrophy (FSHD) at the 28th Annual FSHD Society International Research Congress. The company plans to seek regulatory approval in Q3 2021 to commence clinical trials. ARO-DUX4 demonstrated deep knockdown of DUX4 in mouse models, preventing muscle degeneration and related symptoms. The therapy addresses a significant unmet need in FSHD, where no effective treatments exist.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced positive interim results from the Phase 1/2 study of ARO-HSD, an RNA interference therapeutic targeting liver diseases, including nonalcoholic steatohepatitis (NASH). The study showed a mean 84% reduction in hepatic HSD17B13 mRNA and an average 46% decrease in alanine aminotransferase (ALT) levels after just two doses. The treatment was well-tolerated, with no significant safety concerns reported. These findings position ARO-HSD as a promising candidate for later-stage clinical studies, reinforcing HSD17B13's role as a therapeutic target.

Arrowhead Pharmaceuticals and Horizon Therapeutics have entered into a global collaboration for ARO-XDH, an investigational RNAi therapeutic for uncontrolled gout. Arrowhead will handle preclinical development, while Horizon will manage clinical development and commercialization. Arrowhead will receive $40 million upfront, with potential total milestone payments of up to $660 million plus royalties in the low- to mid-teens range on product sales. This partnership aims to address the unmet treatment needs in gout, affecting over nine million patients in the U.S.